Carrier and Bioreactor Red Blood Cells for Drug Delivery and Targeting

by J. R. Deloach

Publisher: Elsevier Science Pub Co

Written in English
Published: Pages: 210 Downloads: 647
Share This

Subjects:

  • Haematology,
  • Immunology,
  • Medical microbiology & virology,
  • Pharmacology,
  • Erythrocytes,
  • Drug Delivery Systems,
  • Medical Hematology,
  • Medical / Nursing,
  • Health/Fitness,
  • Hematology,
  • Biotechnology,
  • Bioreactors,
  • Congresses,
  • Drug targeting

Edition Notes

ContributionsJames L. Way (Editor)
The Physical Object
FormatHardcover
Number of Pages210
ID Numbers
Open LibraryOL9267003M
ISBN 100080424961
ISBN 109780080424965

Influence of red blood cells on nanoparticle targeted delivery in microcirculation. Soft Matter 8, – ().Crossref, CAS, Google Scholar; 27 Müller K, Fedosov DA, Gompper G. Margination of micro- and nano-particles in blood flow and its effect on drug delivery. Sci. Rep. 4, ().Crossref, Medline, CAS, Google Scholar. The methodology is applicable to drugs that are effective while still attached to a red blood cell, although the researchers say that slow release from the red blood cell surface is also feasible.   Xconomy Boston — [Updated 6/21/17, below.] The main role of red blood cells is to carry life-sustaining oxygen throughout the body. Rubius Therapeutics believes these cells .   The isolated cells were cultured at 37 °C with 5% CO 2 at a cell density of 10 4 cells/cm 2. After culturing for 24 hours, the non-adherent cells were removed by washing with PBS.

biomimetic drug delivery system and as a nanoreactor. It is important to highlight that, even though it is definitely possible to form nanosized vesicles with a narrow size distribution from both cancer cells and red blood cells, actually only NERs can be used to efficiently entrap a .   A new drug-delivery technology which uses red blood cells (RBCs) to shuttle nano-scale drug carriers, called RBC-hitchhiking (RH), has been found in animal models to . A new drug-delivery technology which uses red blood cells (RBCs) to shuttle nano-scale drug carriers, called RBC-hitchhiking (RH), has been found in animal models to dramatically increase the concentration of drugs ferried precisely to selected organs, according to a study published in Nature Communications this month by researchers from the Perelman School of Medicine. Nonspherical carriers imitating the hemodynamic properties of platelets 33 or red blood cells (RBCs) 34,35 circulate in model microfluidic systems and animals for extended periods of time, exceeding the limits of traditional nanocarriers. 34 Elongated PEG polymeric filomicelles that align with blood flow and thereby avoid collisions with.

A Duke rheumatologist and researcher is helping develop a novel drug delivery system for patients with inflammatory arthritis using lasers to trigger the release of drugs injected into red blood cells (RBC) when the cells circulate in affected joints. Teresa Tarrant, MD, a Duke rheumatologist with training in both immunology and rheumatology, says the precisely timed release of medicine within. Nanoparticles hitchhike on red blood cells: a potential new method for drug delivery 27 June Polymer nanoparticles attach to red blood cells and remain in circulation for prolonged times.

Carrier and Bioreactor Red Blood Cells for Drug Delivery and Targeting by J. R. Deloach Download PDF EPUB FB2

Get this from a library. Carrier and bioreactor red blood cells for drug delivery and targeting: proceedings of the Fifth ISURE Conference held in San Antonia [sic], Texas, USA on October [J R DeLoach; J L Way; International Society for Use of Resealed Erythrocytes as Carriers and Bioreactors.

International Meeting]. Red blood cells (RBCs) constitute a unique drug delivery system as a biologic or hybrid carrier capable of greatly enhancing pharmacokinetics, altering pharmacodynamics (for example, by changing margination within the intravascular space), and modulating immune responses to Cited by: Carrier and bioreactor red blood cells for drug delivery and targeting: proceedings of the Fifth ISURE [International meeting], Conference held in San Antonio, Texas, on October / ed.

J.R. Deloach, J.L. Way. Red blood cells (RBCs), the “innate carriers” in blood vessels, are gifted with many unique advantages in drug transportation over synthetic drug delivery systems (DDSs).

Herein, a tumor angiogenesis targeting, light stimulus‐responsive, RBC‐based DDS is developed by incorporating various functional components within the RBC by:   Because of the properties listed above, RBC could be employed as drug carriers for different purposes: (a) they could be loaded by an active payload (i.e., an enzyme) and thus be used as circulating bioreactors to remove undesired molecules from the blood stream; (b) they could be used as a drug delivery system providing a sustained release Cited by: Magnani M.

et al. () Red Blood Cells as Advanced Drug Delivery Systems for Antiviral Nucleoside Analogues. In: Magnani M., DeLoach J.R. (eds) The Use of Resealed Erythrocytes as Carriers and Bioreactors. Engineered human RBCs are attractive carriers for the introduction of novel therapeutics, immunomodulatory agents, and diagnostic imaging probes into the human body.

Normal murine and human RBCs can be produced in tissue culture from progenitors; we have introduced genes into these cells encoding surface proteins that can be covalently and site-specifically modified on the cell surface.

These carrier RBC-preparations may serve as an alternative sustained cell delivery system for the in vivo administration of rHuEpo. red cell delivery systems recombinant human erythropoietin erythrocyte morphology anaemia peptide drugs Carrier and Bioreactor red blood cells for drug delivery and targeting, vol, Great Britain, Advances in.

Furthermore, the pharmacokinetics of any drug can be potentially manipulated by using the erythrocytes as a delivery system. This book, The Use of Resealed Erythrocytes, is based on the fourth meeting of the "International Society for the Use of Resealed Erythrocytes as Carriers and Bioreactors" (I.

E.), held in Urbino, Italy, in   Drug-loaded erythrocytes can operate through one of the three main mechanisms of action: extension of circulation half-life (bioreactor), slow drug release, or specific organ targeting.

Although the clinical development of erythrocyte carriers is confronted with regulatory and development process challenges, industrial development is expanding.

Author(s): DeLoach,J R(John R.); Way,J L(James L.); International Society for the Use of Resealed Erythrocytes as Carriers and Bioreactors.

The majority of these macrophages (74–81%) are immediately sequestered in the liver and in the spleen (13–18%), suggesting that the system is best suited for as a targeting system than as a drug delivery system.

Erythrocytes (red blood cells, RBCs) constitute potential biocompatible carriers for different bioactive substances, including. Abstract. Until rcently the only biomedical use of erythrocytes was in transfusion medicine to restore normal oxygen delivery.

In recent years a number of procedures have been developed to load these cells with macromolecules including enzymes, drugs, antigens, etc. (Magnani and DeLoach, b). Red blood cells are the blood cells that carry blood cells contain hemoglobin and it is the hemoglobin which permits them to transport oxygen and carbon obin, aside from being a transport molecule, is a gives the cells their red color and their name.

The abbreviation for red blood cells is RBCs. ISBN: OCLC Number: Description: 1 online resource ( pages): illustrations. Contents: Red blood cell loading: a selection of procedures / L. Rossi, S.

Serafini & M. Magnani --Towards activated release of payloads from carrier erythrocytes / A.M. Rollan & A.P. McHale --Targeting drug-loaded red blood cells / M. Magnani, L. Rossi & G. Brandi --Streptavidin. Red blood cell loading: a selection of procedures / Luigia Rossi, Sonja Serafini and Mauro Magnani --Towards activated release of payloads from carrier erythrocytes / A.M.

Rollan and A.P. McHale --Targeting drug loaded red blood cells / Mauro Magnani, Luigia Rossi and Giorgio Brandi --Streptavidin-mediated coupling of therapeutic proteins to. The book gives a better understanding of the role of the resealed erthytocytes as potential slow release carriers for drugs and enzymes, being very helpful to scientists working in the fiels as well as to clinicians for treatment improvement.

-- Revue Roumaine de biologie, December   The potential use of red blood cells as a carrier system for the transport and delivery of pharmacological substances (drugs, enzymes, nucleic acids, genes) is well documented.

One potential application is the delivery of these substances to cells responsible for or capable of erythrophagocytosis, which are located primarily in the liver and. Red blood cells (RBC) are actually exploited as innovative drug delivery systems with unconventional and convenient properties.

Because of a long in vivo survival and a non-random removal from circulation, RBC can be loaded with drugs and/or contrasting agents without affecting these properties and maintaining the original immune competence.

However, native or drug-loaded RBC. These strategies include their application as circulating bioreactors, targeting the monocyte–macrophage system, the coupling of enzymes to the surface of the erythrocyte and the engineering of CD34+ hematopoietic precursor cells for the expression of therapeutic enzymes.

Vascular Drug Delivery Using Carrier Red Blood Cells: Focus on RBC. A new drug-delivery technology which uses red blood cells to shuttle nano-scale drug carriers, called RBC-hitchhiking, has been found in animal models to dramatically increase the concentration of. For example, Alapan, et al.

() generated bacterial microswimmers which were bound tightly with doxorubicin and superparamagnetic iron oxide nanoparticles (SPIONs) loaded soft red blood cells onto their surface via biotin-avidin-biotin binding complex for on-demand delivery and release of chemo-therapeutic drugs (Fig.

2b). Erythrocyte engineering for drug delivery and targeting. Carriers and Bioreactors (Magnani, M. and DeLoach, J. R., eds.), an intriguing strategy based on the use of red blood cells (RBC. The potential therapeutic applications of carrier erythrocytes as a drug delivery system cover a wide spectrum of pharmacologic as well as therapeutic targets mainly based on the intravenous slow drug release as well as the targeted drug delivery.Some typical examples of drugs exploited for delivery using carrier erythrocytes and their suggested therapeutic targets in the body are.

Nanocarriers for drug delivery. Nanomedicine is a rapidly developing area that is revolutionizing cancer diagnosis and therapy. Nanoparticles.

The percent red blood cell volume in a particular blood vessel. Bio-inspired drug carrier designs: A novel approach to designing VTCs and other types of drug carriers by mimicking biophysical and biochemical features of natural blood cells in effort to improve drug carrier performance and targeting efficiency.

Multireceptor targeting. Xiao Han, Chao Wang and Zhuang Liu, Red Blood Cells as Smart Delivery Systems, Bioconjugate Chemistry, ().

Crossref Song Ding, Colin P. O'Banion, Joshua G. Welfare and David S. Lawrence, Cellular Cyborgs: On the Precipice of a Drug Delivery Revolution, Cell Chemical Biology, ().

On page Z. Liu and colleagues introduce a tumor angiogenesis targeting, near‐infrared light stimulus‐response red blood cell (RBC)‐based drug delivery by. Contents: Red blood cell loading: a selection of procedures / L.

Rossi, S. Serafini & M. Magnani -- Towards activated release of payloads from carrier erythrocytes / A.M. Rollan & A.P. McHale -- Targeting drug-loaded red blood cells / M. Magnani, L. Rossi & G. Brandi -- Streptavidin-mediated coupling of therapeutic proteins to carrier.

Drug delivery by red blood cells: vascular carriers designed by Mother Nature Article Literature Review (PDF Available) in Expert Opinion on Drug Delivery 7(4) March with Reads.

The need for an effective drug delivery system is underscored by the constraints associated with the collateral effects of using drugs at high doses. Many approaches to the problem of controlled and targeted drug delivery such as a polymeric sustained release system, liposomal drug carriers, and antibody drug carriers have been proposed and.Get this from a library!

The Use of Resealed Erythrocytes as Carriers and Bioreactors. [Mauro Magnani; J R DeLoach] -- Until recently the only biomedical use of erythrocytes was in transfusion medicine to restore a normal oxygen delivery.

The development of a. A drug carrier is any substrate used in the process of drug delivery which serves to improve the selectivity, effectiveness, and/or safety of drug administration. 3 4. DRUG CARRIER PROCESS: 4 5.

Particulate Carrier: • Drug carriers achieve different goals: bioavailability, stability, preventing the drug interactions.